
.png)
Click here to watch the recording of this live conversation.
It’s 11:47 p.m. on the last day of the quarter. One accountant is still at her desk, staring at a 32-tab accrual workbook full of broken formulas. Her CRO accrual won’t reconcile; she has four trials to close, and the auditors arrive in nine days.
That exact scene opened our recent webinar on clinical accounting for private biotech, led by Tyler Lythgoe, Auxilius’s Senior Director of Accounting and Operations, and VP of Marketing Peter Kinchley. Drawing on his experience at EY and Connor Group, and from advising over 30 sponsors at Auxilius, Tyler broke down the accrual challenges he most often sees at scaling biotechs and what to do about it.
That late-night scramble isn't an isolated fire drill; it’s the predictable breaking point of managing multi-study clinical accounting in spreadsheets. As a biotech moves from a single trial to a growing pipeline, manual processes quietly buckle.
Across almost every scaling sponsor, Tyler sees the same three pressures collide:
Consequently, month-end close dissolves into four exhausting tasks:
Tyler is quick to note that AI won’t replace the accounting team because it cannot replace judgment, context, or accountability. Estimating requires professional judgment, which is where controllers earn their keep. Gathering, reconciling, and documenting, however, are the biggest time sinks, and the most automatable.
To break out of the spreadsheet trap, Tyler shared three core lessons for scaling clinical accruals without losing your sanity:
Picture a controller whose company just jumped from two trials to five. Her CFO wants an 8-day close instead of a 15-day close; auditors are demanding stronger evidence of review, and those three new trials brought just one new hire. Working harder won’t bridge that gap. Instead, Tyler recommends weaving the close, the controls, and team onboarding into a single, repeatable workflow:
To put this into practice, the Expense Detail page in Auxilius replaces the 32-tab workbook with a single system of record. Every contract is tracked at the granularity that its materiality warrants, activity by activity for a CRO, or by GL account for a smaller vendor. Teams can pick a consistent expense source for each period (an internal forecast-driven estimate, the CRO’s estimate, or EDC-based expense) and view them side-by-side as a built-in reasonableness check.
During our live demo, seeing a $5.2 million internal estimate sit right alongside a $5.4 million estimate from the CRO gives preparers comfort in the vendor’s numbers. When you do disagree with the CRO, you adjust right in place: Tyler cut a $50,000 site feasibility line from 100% to 50% complete based on clinical operations feedback, and the system automatically captured his rationale and supporting files. With ERP invoices syncing automatically, the team spends the close on actual judgment and review rather than data entry.
"Our CRO already reports investigator spend, so why use EDC?"
The answer comes down to timing. CRO reports typically reflect what has been paid or invoiced, which often lags work performed by months. Under GAAP accrual accounting, a patient visit cost is incurred at the time the visit occurs, and EDC records that exact date in a more timely fashion than the payments process. Using EDC isn't duplicating work; it is simply a more accurate, complete source for clinical accruals.
Does this level of rigor matter before a company is formally subject to SOX 404(a)? "I’ve never seen anyone regret setting up stronger controls earlier than later," Tyler explained. Whether you are eyeing an IPO, a strategic partnership, or an acquisition, an audit is coming and prepared teams don't scramble.
In Auxilius, EDC visit data is mapped directly to each site agreement’s fee schedule assigning a dollar value for each transaction. The data refreshes seamlessly and routes for documented sign-off. To ensure ironclad data integrity, automated row-count checks reconcile source records against system outputs, filtering out duplicate entries so expenses aren't overstated, while a clean patient-status view makes it easy to tie out numbers with clinical operations.
If you have one trial running today and three more that are in the planning stage, Tyler’s advice is simple: build your control framework before a single dollar moves. Designing consistent controls upfront prevents teams from spinning up frantic, one-off spreadsheets every time a new protocol launches.
That upfront planning now happens more seamlessly with Atlas, Auxilius’s new study planning product. Modeling a Phase 2 non-small cell lung cancer trial with 200 patients across 80 sites during the webinar, Tyler was able to instantly generate a projected CRO budget after entering study criteria based on benchmarking data in the Auxilius platform. FP&A walks away with a fast, defensible budget forecast, while accounting gets early visibility into upcoming contracts and the controls they will demand.
Tyler noted that AI is already adept at flagging variances and taking a first pass at raw data, but will never replace human estimates, professional reviews, or signoffs. A sound control system, not a heroic late-night spreadsheet session, is what truly lets you stand behind your clinical accruals.
Want to see how Auxilius can help automate your close? Book a demo to learn more.
.png)